Paper Details
- Home
- Paper Details
Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
Author: BangSoo-Mee, JungEun Hee, KimJee Hyun, KimJi-Won, KimJin Won, KimKui-Jin, KimSang-A, KimSe Hyun, KimYu Jung, LeeJeong-Ok, LeeJi Yun, LeeJong Seok, LeeJu Hyun, LeeKeun-Wook, NamMilang, ParkHyejoo, SuhKoung Jin, SungJi Hea
Original Abstract of the Article :
Recent evidence has highlighted the role of hepatocyte growth factor (HGF) as a putative biomarker to predict EGFR inhibitor resistance. This study investigated the impact of plasma HGF levels on EGFR inhibition and the counter effect of MET inhibition in KRAS, NRAS, and BRAF (RAS/RAF) wild-type col...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1007/s00432-021-03872-4
データ提供：米国国立医学図書館（NLM）
Overcoming Cetuximab Resistance: A New Oasis in the Desert of Colorectal Cancer Treatment
The battle against colorectal cancer is a long and arduous journey through a vast desert of challenges. Cetuximab, an EGFR inhibitor, is a valuable weapon in this fight, but its effectiveness can be hampered by resistance. This study explores the role of hepatocyte growth factor (HGF) in cetuximab resistance and investigates the potential of MET inhibition to overcome this obstacle. The researchers sought to find new paths to victory in this challenging battle against cancer.
Unraveling the Mechanisms of Cetuximab Resistance: Finding Clues in the Desert of Cancer Biology
The study found that high plasma HGF levels are associated with cetuximab resistance in colorectal cancers. This finding suggests that HGF plays a significant role in the development of resistance to EGFR inhibitors. This discovery could lead to new strategies for overcoming resistance, potentially providing a lifeline for patients who have stopped responding to treatment.
Targeting MET Inhibition: A Potential Oasis of Hope
The study suggests that inhibiting MET, a receptor for HGF, can overcome cetuximab resistance in colorectal cancers. This finding offers a new avenue for treatment, potentially restoring the effectiveness of cetuximab for patients who have developed resistance. It's like finding a hidden oasis in the desert of cancer treatment, offering a new source of hope and potentially extending the benefits of this valuable therapy.
Dr.Camel's Conclusion
This research provides valuable insights into the mechanisms of cetuximab resistance in colorectal cancers. By understanding the role of HGF and exploring the potential of MET inhibition, we may be able to develop new strategies for overcoming resistance and extending the benefits of this important therapy. This research represents a promising step forward in the ongoing quest for more effective treatments for colorectal cancer, offering hope for a future where the desert of this disease becomes a little less desolate.
Date :
- Date Completed 2022-09-28
- Date Revised 2022-09-28
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.